Steve Worland, eFFECTOR CEO

Sur­prise piv­ot rocks eF­FEC­TOR's I/O plans — al­though ex­ecs promise big­ger slice of the NSCLC mar­ket in the long run

When eF­FEC­TOR Ther­a­peu­tics went pub­lic last sum­mer on the coat­tails of a re­verse merg­er with Lo­cust Walk’s SPAC, the po­ten­tial of its lead drug, tomivosert­ib, as a com­bo agent with Mer­ck’s flag­ship PD-1 Keytru­da was hailed as the main draw.

But the biotech is now ax­ing those plans and es­sen­tial­ly start­ing over.

In a sur­prise move, San Diego-based eF­FEC­TOR said it’s halt­ing the de­vel­op­ment of tomivosert­ib in non-small cell lung can­cer pa­tients who have al­ready pro­gressed on Keytru­da monother­a­py af­ter run­ning in­to en­roll­ment chal­lenges in a Phase IIb tri­al.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.